In past, BCR-ABL protein modelling studies have led to unravel mechanisms of TKI resistance in CML and to design novel drugs to treat drug-resistant CML (Ozkan et al., 2018; Altıntop et al., 2017). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.